Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

‘A good day’: FDA approves world’s first RSV vaccine

Green light from US regulatory agency for GSK’s jab caps off a decades-long quest.
  1. Myriam Vidal Valero
    View author publications

    You can also search for this author in PubMed  Google Scholar

The US Food and Drug Administration (FDA) has approved GSK’s vaccine against respiratory syncytial virus (RSV) for use in people aged 60 years and older. This is the first RSV vaccine to gain approval anywhere in the world, and researchers are celebrating.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 617, 234-235 (2023)

doi: https://doi.org/10.1038/d41586-023-01529-5

Updates & Corrections

  • Correction 04 May 2023: An earlier version of this story spelled researcher Jason McLellan’s name incorrectly.

References

  1. Papi, A. et al. N. Engl. J. Med. 388, 595–608 (2023).

    Article  PubMed  Google Scholar 

  2. Kim, H. Y. et al. Am. J. Epidemiol. 89, 422–434 (1969).

    Article  PubMed  Google Scholar 

  3. McLellan, J. S. et al. Science 342, 592–598 (2013).

    Article  PubMed  Google Scholar 

  4. Kampmann, B. et al. N. Engl. J. Med. 388, 1451–1464 (2023).

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links